Merck Plans To ‘Tuck In’ Imago And Its Phase III-Ready Hematologic Candidate

 
• By Joseph Haas

After not closing a deal this year on Seagen, Merck takes a smaller step with a $1.35bn bid for Imago and its candidate for multiple myeloproliferative neoplasm indications.

Myeloproliferative neoplasms
Merck will acquire Imago's lead candidate for myeloproliferative neoplasms • Source: Shutterstock

More from Deals

More from Business